Your browser doesn't support javascript.
Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients.
Balestrieri, Emanuela; Minutolo, Antonella; Petrone, Vita; Fanelli, Marialaura; Iannetta, Marco; Malagnino, Vincenzo; Zordan, Marta; Vitale, Pietro; Charvet, Benjamin; Horvat, Branka; Bernardini, Sergio; Garaci, Enrico; di Francesco, Paolo; Sinibaldi Vallebona, Paola; Sarmati, Loredana; Grelli, Sandro; Andreoni, Massimo; Perron, Hervé; Matteucci, Claudia.
  • Balestrieri E; Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
  • Minutolo A; Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
  • Petrone V; Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
  • Fanelli M; Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
  • Iannetta M; Department of Systems Medicine, University of Rome Tor Vergata, Rome 00133, Italy; Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome 00133, Italy.
  • Malagnino V; Department of Systems Medicine, University of Rome Tor Vergata, Rome 00133, Italy; Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome 00133, Italy.
  • Zordan M; Department of Systems Medicine, University of Rome Tor Vergata, Rome 00133, Italy; Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome 00133, Italy.
  • Vitale P; Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome 00133, Italy.
  • Charvet B; International Center for Infectiology Research (CIRI), INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure de Lyon, University of Lyon, Lyon, France; Geneuro - Innovation, Lyon 69008, France.
  • Horvat B; International Center for Infectiology Research (CIRI), INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure de Lyon, University of Lyon, Lyon, France.
  • Bernardini S; Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
  • Garaci E; IRCCS San Raffaele Pisana, Rome 00163, Italy.
  • di Francesco P; Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
  • Sinibaldi Vallebona P; Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy; Institute of Translational Pharmacology, National Research Council, Rome 00133, Italy.
  • Sarmati L; Department of Systems Medicine, University of Rome Tor Vergata, Rome 00133, Italy; Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome 00133, Italy.
  • Grelli S; Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy; Virology Unit, Policlinic of Tor Vergata, Rome 00133, Italy.
  • Andreoni M; Department of Systems Medicine, University of Rome Tor Vergata, Rome 00133, Italy; Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome 00133, Italy.
  • Perron H; Geneuro - Innovation, Lyon 69008, France; University of Lyon, Lyon 69007, France.
  • Matteucci C; Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy. Electronic address: matteucci@med.uniroma2.it.
EBioMedicine ; 66: 103341, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-1184943
ABSTRACT

BACKGROUND:

Despite an impressive effort in clinical research, no standard therapeutic approach for coronavirus disease 2019 (COVID-19) patients has been established, highlighting the need to identify early biomarkers for predicting disease progression and new therapeutic interventions for patient management. The present study aimed to evaluate the involvement of the human endogenous retrovirus -W envelope (HERV-W ENV) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection considering recent findings that HERVs are activated in response to infectious agents and lead to various immunopathological effects. We analysed HERV-W ENV expression in blood cells of COVID-19 patients in correlation with clinical characteristics and have discussed its potential role in the outcome of the disease.

METHODS:

We analysed HERV-W ENV expression in blood samples of COVID-19 patients and healthy donors by flow cytometry and quantitative reverse transcriptase PCR analysis, and evaluated its correlation with clinical signs, inflammatory markers, cytokine expression, and disease progression.

FINDINGS:

HERV-W ENV was highly expressed in the leukocytes of COVID-19 patients but not in those of healthy donors. Its expression correlated with the markers of T-cell differentiation and exhaustion and blood cytokine levels. The percentage of HERV-W ENV-positive lymphocytes correlated with inflammatory markers and pneumonia severity in COVID-19 patients. Notably, HERV-W ENV expression reflects the respiratory outcome of patients during hospitalization.

INTERPRETATION:

Given the known immuno- and neuro-pathogenicity of HERV-W ENV protein, it could promote certain pathogenic features of COVID-19 and therefore serve as a biomarker to predict clinical progression of disease and open to further studies for therapeutic intervention.

FUNDING:

Information available at the end of the manuscript.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pregnancy Proteins / T-Lymphocytes / Gene Products, env / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: EBioMedicine Year: 2021 Document Type: Article Affiliation country: J.ebiom.2021.103341

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pregnancy Proteins / T-Lymphocytes / Gene Products, env / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: EBioMedicine Year: 2021 Document Type: Article Affiliation country: J.ebiom.2021.103341